Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis
Andrea Boutros(The University of Sydney), Francesco Spagnolo(Martin University), P. Pronzato(Accademia Nazionale dei Lincei), Matteo Fraguglia(University of Genoa), Elena Croce(Ospedale Policlinico San Martino), Marco Bruzzone(Ospedale Policlinico San Martino), Lucia Del Mastro(Ospedale Policlinico San Martino), Fabio Catalano(Ospedale Policlinico San Martino), Matteo Lambertini(Ospedale Policlinico San Martino), Marcello Ceppi(Ospedale Policlinico San Martino), Carlo Genova(Ospedale Policlinico San Martino), Enrica T. Tanda(Ospedale Policlinico San Martino), Federica Cecchi(Ospedale Policlinico San Martino), Luca Arecco(Ospedale Policlinico San Martino)
Cited by 38
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Cancer and fertility preservation: international recommendations from an expert meeting
|BMC Medicine|2016|779
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
|Annals of Oncology|2023|286
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282